register

News & Trends - MedTech & Diagnostics

Crohn’s disease: Implantable device holds promise for long-term remission

Health Industry Hub | February 7, 2024 |

MedTech & Diagnostics News: Gastroenterologists at Austin Health have successfully implanted an electrical nerve stimulation device into a patient with Crohn’s disease, aiming to induce long-term remission post-surgery.

Crohn’s disease often necessitates bowel surgery to remove damaged sections. Unfortunately, the disease frequently resurfaces, compelling patients to undergo further surgeries and rely on lifelong drug therapies.

AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, was listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with severe Crohn’s disease (CD). This Janus Kinase (JAK) inhibitor represents the first novel molecule in seven years to secure a place on the PBS for treating CD.

Professor John Furness, co-investigator and leader of The Florey’s Digestive Physiology and Nutrition Laboratories, emphasised the transformative impact of this breakthrough medical device on the lives of Crohn’s patients.

He stated, “By stimulating anti-inflammatory nerves and addressing inflammation early, the recurrent inflammation and associated scar tissue development can hopefully be prevented altogether, meaning patients will avoid the cycle of surgery and recovery.”

Associate Professor Peter De Cruz, Director of Inflammatory Bowel Disease Service at Austin Health, highlighted the significant impact of Crohn’s disease on Australians, particularly during crucial life stages.

“Australia has among the highest incidence of Crohn’s disease in the world, and affects young people in their 20s to 30s at a time when they are trying to study, enter the workforce or commence families,” he noted.

The medical device, developed by Professor James Fallon, Chief Technology Officer, and Head of Research at the Bionics Institute, was recently implanted onto the vagus nerve of Crohn’s patient Anthony Becker. Mr Becker, who has battled Crohn’s for decades, is determined to confront the disease head-on, hoping to maintain a quality of life free from surgeries.

Professor Fallon explained the device’s mechanism, stating, “The vagus nerve controls many functions in the body, such as digestion, heart rate, and the immune system. The device is made up of tiny electrodes that stimulate the vagus nerve to trigger the body’s natural defences and prevent inflammation from damaging the gut.”

If successful, the implant could offer a “set-and-forget” treatment, powered by a small battery under the skin.

Associate Professor De Cruz expressed optimism, saying, “Up to 80% of Crohn’s sufferers will require surgery at some point in their lives. It’s hoped that eventually this new device will work as a set and forget, allowing patients to continue with their lives without the fear of ongoing treatment with medication.”

The current study aims to confirm the safety and efficacy of the device for Crohn’s sufferers, providing crucial data to understand if remission can be sustained after surgery.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.